SEC Form 10-Q filed by Theravance Biopharma Inc.
$TBPH
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/12/2025 | $28.00 | Buy | B. Riley Securities |
| 8/6/2024 | $15.00 → $10.00 | Outperform → Market Perform | Leerink Partners |
| 4/12/2024 | $21.00 | Buy | BTIG Research |
| 1/8/2024 | Outperform → In-line | Evercore ISI | |
| 5/23/2022 | $12.00 | Outperform | SVB Leerink |
| 3/2/2022 | $10.00 → $11.00 | Underweight | Morgan Stanley |
| 2/24/2022 | $8.00 → $12.00 | Buy | HC Wainwright & Co. |
| 11/5/2021 | $7.00 → $12.00 | Underweight → Neutral | JP Morgan |
DUBLIN, Nov. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:30 AM ET. To register, click here. The event will feature Horacio Kaufmann, MD (Dysautonomia Center, NYU Langone Health), who will join company management to discuss the unmet medical need for symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA), a chronic, debilitating condition caused by autonomic dysfunction that is present in ~80% of
DUBLIN, Nov. 19, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) today announced that management will participate in the following investor conferences in December 2025: 8th Annual Evercore Healthcare ConferenceLocation: Coral Gables, FLFormat: Fireside ChatDate: Thursday, December 4, 2025Time: 8:20-8:40 AM ETWebcast Oppenheimer Movers in Rare Disease SummitLocation: New York, NYFormat: Panel Discussion - Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving CatalystsDate: Thursday, December 11, 2025Time: 2:15-2:45 PM ET Therav
YUPELRI® net sales reached an all-time high of $71.4 million, recognized by Viatris, up 15% year-over-year1, and achieved record brand profitabilityOpen-label portion of the pivotal Phase 3 CYPRESS study of ampreloxetine now complete; topline readout on track for Q1 2026Company to host an ampreloxetine focused virtual Key Opinion Leader (KOL) event for investors on December 8, 2025TRELEGY year-to-date sales on track to achieve $50 million milestone in 20252Strong balance sheet with $333 million in cash and no debtDUBLIN, Nov. 10, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today reported financial and operational results for the thi
10-Q - Theravance Biopharma, Inc. (0001583107) (Filer)
144 - Theravance Biopharma, Inc. (0001583107) (Subject)
8-K - Theravance Biopharma, Inc. (0001583107) (Filer)
B. Riley Securities initiated coverage of Theravance Biopharma with a rating of Buy and set a new price target of $28.00
Leerink Partners downgraded Theravance Biopharma from Outperform to Market Perform and set a new price target of $10.00 from $15.00 previously
BTIG Research initiated coverage of Theravance Biopharma with a rating of Buy and set a new price target of $21.00
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
4/A - Theravance Biopharma, Inc. (0001583107) (Issuer)
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
DUBLIN, Nov. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:30 AM ET. To register, click here. The event will feature Horacio Kaufmann, MD (Dysautonomia Center, NYU Langone Health), who will join company management to discuss the unmet medical need for symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA), a chronic, debilitating condition caused by autonomic dysfunction that is present in ~80% of
YUPELRI® net sales reached an all-time high of $71.4 million, recognized by Viatris, up 15% year-over-year1, and achieved record brand profitabilityOpen-label portion of the pivotal Phase 3 CYPRESS study of ampreloxetine now complete; topline readout on track for Q1 2026Company to host an ampreloxetine focused virtual Key Opinion Leader (KOL) event for investors on December 8, 2025TRELEGY year-to-date sales on track to achieve $50 million milestone in 20252Strong balance sheet with $333 million in cash and no debtDUBLIN, Nov. 10, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today reported financial and operational results for the thi
Ampreloxetine clinical development program to be featured in four presentations at the upcoming International Symposium on The Autonomic Nervous SystemTopline results from the ongoing Phase 3 CYPRESS study of ampreloxetine anticipated in Q1 2026DUBLIN, Oct. 29, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) today announced that it will be participating at the 36th International Symposium on the Autonomic Nervous System, organized by the American Autonomic Society (AAS), taking place November 5-8, 2025, in Clearwater Beach, FL. The Company will have one platform presentation and three poster presentations on its clinical development program for ampreloxetine, a potential first-
SC 13G/A - Theravance Biopharma, Inc. (0001583107) (Subject)
SC 13G/A - Theravance Biopharma, Inc. (0001583107) (Subject)
SC 13G/A - Theravance Biopharma, Inc. (0001583107) (Subject)
Enters into Cooperation Agreement with Shareholder Irenic Capital Reaffirms Intention to Return All Excess Capital to Shareholders and MaximizeShareholder Value DUBLIN, Dec. 21, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ:TBPH) today announced the appointment to its Board of Directors of Jeremy Grant, who serves as a Special Advisor to Irenic Capital Management LP ("Irenic"). With the addition of Mr. Grant, Theravance has appointed four new directors to the Board since 2020. "We are pleased to welcome Jeremy to the Theravance Board a
Believes Jim Kelly of Weiss Asset Management Will Bring Important Ownership Mentality to the Boardroom Encourages the Board to Continue Taking Concrete Steps to Improve Capital Allocation, Enhance Corporate Governance and Review Strategic Alternatives Irenic Capital Management, LP (together with its affiliates, "Irenic" or "we"), a top shareholder of Theravance Biopharma, Inc. (NASDAQ:TBPH) ("Theravance" or the "Company"), today issued the following statement regarding the Company's appointment of Jim Kelly, Managing Director at Weiss Asset Management, to the Board of Directors (the "Board"): "Irenic welcomes the appointment of Jim Kelly to the Theravance Board. We respect and admire
DUBLIN, April 11, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced the appointment of Jim Kelly, Managing Director at Weiss Asset Management, the Company's second largest shareholder, to its Board of Directors. With the appointment of Mr. Kelly, four new directors have joined the Company's Board of Directors since 2018 as part of its ongoing board refreshment process. "We are pleased to welcome Jim Kelly to the Theravance Board of Directors. Weiss Asset Management has been one of our largest shareholders si